Timeline
2019
2020
- Langen Junior Science Award
- WHO Declares Pandemic
- Paul Ehrlich and Ludwig Darmstaedter Prize
- Supply Bottleneck for Pneumococcal Vaccines
- Blood Donation Remains Possible
- Convalescent Plasma: First Clinical Trial
- COVID-19 Vaccines: First Clinical Trial
- Marketing Authorisation of Gene Therapy
- COVID-19 Vaccines: Second Clinical Trial Approved
- German Presidency of the EU Council
- COVID-19 Vaccines: Two Clinical Trials Approved
- Another Clinical Trial Approved
- Start of Two Rolling Review Procedures
- Allergen Products: European Standards
- Allergen Product: First European Marketing Authorisation
- COVID-19 Peptide Vaccine: First Clinical Trial
- COVID-19 Vaccine: Third Rolling Review Procedure
- Validation of COVID-19 Rapid Tests
- First Marketing Authorisation of a COVID-19 Vaccine
- SafeVac App Available
On 22 April 2021, the Paul-Ehrlich-Institut approves the first phase I/II clinical trial of a vaccine candidate against COVID-19 in Germany. BioNTech, a Mainz-based company, is testing a vaccine using the novel mRNA technology. The Paul-Ehrlich-Institut launches a series of virtual press briefings, at which journalists can talk, on an equal footing, to President Prof. Cichutek, experts from the Paul-Ehrlich-Institut and the manufacturers, and receive information on the development, marketing authorisation and safety of COVID-19 vaccines.